Kinnov-Therapeutics is in French magazine Biotech Finance this month. KT wants to raise 1M€ for its Phase IIb clinical trials in alcohol addiction.
Our patented drug composition is a first in class treatment of the cause of addiction. Patients recruitments will start shortly.

Read the article in PDF.